Lumbar belt could help with back pain

Publicly released:
International
Image by Kevin from Pixabay
Image by Kevin from Pixabay

If you suffer from lower back pain, a soft, extensible lumbar belt might help, according to international researchers. The research, which was funded by Thusane, a company which sells medical compression products, consisted of a randomised clinical trial of 168 adults with nonspecific back pain lasting between one and six months. After 12 weeks of use averaging around four hours per day for around 4.5 days a week, the team found the belt group had a greater improvement in symptoms than those without the belt. While the authors couldn’t rule out a placebo effect (as those in the belt group would know they’re wearing a belt and this might affect their pain perception or expectations), the team says the use of a belt could be an option to help manage nonspecific low back pain for those who need it.

News release

From: JAMA

Lumbar Belt for Nonspecific Low Back Pain

In this randomized clinical trial, adding a nonrigid lumbar belt to usual care resulted in improved pain and functional disability in patients with nonspecific low back pain lasting 1 to 6 months. These findings suggest that lumbar belts may be considered as a nonpharmacological option for symptom management.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo lifts.
Journal/
conference:
JAMA Network Open
Research:Paper
Organisation/s: Grenoble Alpes University Hospital, France
Funder: This study was funded by Thuasne. Conflict of Interest Disclosures: Drs Grange, Calmels, and Rannou reported receiving personal fees from Thuasne for participation in the scientific committee during the conduct of the study. Dr Calmels reported receiving personal fees from Ipsen and Thuasne outside the submitted work. Dr Rannou reported receiving grants from Assitance Publique Hopitaux de Paris and Programme Hospitalier de Recherche Clinique and personal fees from Expanscience, Pierre Fabre, Axomove, Peptinov, IBSA Pharma, Genevrier, Pfizer, and Merck Sharp & Dohme outside the submitted work. No other disclosures were reported.
Media Contact/s
Contact details are only visible to registered journalists.